Mauna Kea Technologies: 2024 Results and Outlook

Endomicroscopy specialist Mauna Kea Technologies has unveiled its 2024 results. The company faced a challenging year with a 27% decline in revenue to €7.7 million, primarily due to a lack of orders in China and a reduction in Medicare reimbursements in the United States. However, gross margin increased by 12 percentage points to 78%.

Despite these challenges, Mauna Kea launched CellTolerance, targeting a potential €6 billion market for food intolerances. Furthermore, the ongoing safeguard procedure aims to consolidate its financial structure. Looking ahead, the group expects to triple its revenues by 2025 thanks to CellTolerance and by stimulating demand for pancreatic cysts.

Finally, the financing agreement with Vester Finance helps extend the cash flow horizon to July 2025. However, the need for financing remains crucial for business continuity.